Characterizing the anti-HIV activity of papuamide A

Marine Drugs

Volumn 6, Issue 4, 2008, Pages 528-549

  Andjelic, Cynthia D ^a   Planelles, Vicente ^b   Barrows, Louis R ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclic depsipeptide; Entry inhibitor; HIV; Marine metabolite; Papuamide A

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUTYRIC ACID DERIVATIVE; CD4 ANTIGEN; GLYCOPROTEIN GP 120; PAPUAMIDE A; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; EMBRYO; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; MURINE LEUKEMIA VIRUS; PROTEIN EXPRESSION; VESICULAR STOMATITIS VIRUS; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION;

AMPHOTROPIC MURINE LEUKEMIA VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

EID: 57149104208     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md20080027     Document Type: Article

References (57)

1. Gochfeld, D.J.; El Sayed, K.A.; Yousaf, M.; Hu, J.F.; Bartyzel, P.; Dunbar, D.C.; Wilkins, S.P.; Zjawiony, J.K.; Schinazi, R.F.; Schlueter-Wirtz, S.; Tharnish, P.M.; Hamann, M.T. Marine natural products as lead anti-HIV agents. Mini Rev. Med. Chem. 2003, 3(5), 401-424.
2. Tziveleka, L.A.; Vagias, C.; Roussis, V. Natural products with anti-HIV activity from marine organisms. Curr. Top. Med. Chem. 2003, 3(13), 1512-1535.
3. Oku, N.; Gustafson, K.R.; Cartner, L.K.; Wilson, J.A.; Shigematsu, N.; Hess, S.; Pannell, L.K.; Boyd, M.R.; McMahon, J.B.; Neamphamide, A. A new HIV-inhibitory depsipeptide from the Papua New Guinea marine sponge Neamphius huxleyi. J. Nat. Prod. 2004, 67(8), 1407-1411.
4. NIAID, Division of AIDS, HIV/OI/TB Therapeutics Database, Vol. September, 2007.
5. Zampella, A.; D'Auria, M.V.; Paloma, L.G.; Casapullo, A.; Minale, L.; Debitus, C.; Henin, Y. Callipeltin A, an Anti-HIV Cyclic Depsipeptide from the New Caledonian Lithistida Sponge Callipelta sp. J. Am. Chem. Soc. 1996, 118, 6202-6209.
6. Plaza, A.; Gustchina, E.; Baker, H.L.; Kelly, M.; Bewley, C.A.; Mirabamides, A.-D. Depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion. J. Nat. Prod. 2007, 70(11), 1753-1760.
7. Ford, P.W.; Gustafson, K.R.; McKee, T.C.; Shigematsu, N.; Maurizi, L.K.; Pannell, L.K.; Williams, D.E.; de Silva, E.D.; Lassota, P.; Allen, T.M.; Van Soest, R.; Andersen, R.J.; Boyd, M.R. Papuamides A-D, HIV-Inhibitory and Cytotoxic Depsipeptides from the Sponges Theonella mirabilis and Theonella swinhoei Collected in Papua New Guinea. J. Am. Chem. Soc. 1999, 121, 5899-5909.
8. Richman, D.D.; Morton, S.C.; Wrin, T.; Hellmann, N.; Berry, S.; Shapiro, M.F.; Bozzette, S.A. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004, 18(10), 1393-1401.
9. Dalgleish, A.G.; Beverley, P.C.; Clapham, P.R.; Crawford, D.H.; Greaves, M.F.; Weiss, R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312(5996), 763-767.
10. McDougal, J.S.; Kennedy, M.S.; Sligh, J.M.; Cort, S.P.; Mawle, A.; Nicholson, J.K. Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science 1986, 231(4736), 382-385.
11. Rizzuto, C.D.; Wyatt, R.; Hernandez-Ramos, N.; Sun, Y.; Kwong, P.D.; Hendrickson, W.A.; Sodroski, J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280(5371), 1949-1953.
12. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272(5263), 872-877.
13. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R.E.; Hill, C.M.; Davis, C.B.; Peiper, S.C.; Schall, T.J.; Littman, D.R.; Landau, N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381(6584), 661-666.
14. Choe, H.; Farzan, M.; Sun, Y.; Sullivan, N.; Rollins, B.; Ponath, P.D.; Wu, L.; Mackay, C.R.; LaRosa, G.; Newman, W.; Gerard, N.; Gerard, C.; Sodroski, J. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85(7), 1135-1148.
15. Dragic, T.; Litwin, V.; Allaway, G.P.; Martin, S.R.; Huang, Y.; Nagashima, K.A.; Cayanan, C.; Maddon, P.J.; Koup, R.A.; Moore, J.P.; Paxton, W.A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381(6584), 667-673.
16. Wu, L.; Gerard, N.P.; Wyatt, R.; Choe, H.; Parolin, C.; Ruffing, N.; Borsetti, A.; Cardoso, A.A.; Desjardin, E.; Newman, W.; Gerard, C.; Sodroski, J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384(6605), 179-183.
17. Doms, R.W.; Moore, J.P. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 2000, 151(2), F9-14.
18. Chan, D.C.; Fass, D.; Berger, J.M.; Kim, P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89(2), 263-273.
19. Tan, K.; Liu, J.; Wang, J.; Shen, S.; Lu, M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. USA 1997, 94(23), 12303-12308.
20. Weissenhorn, W.; Dessen, A.; Harrison, S.C.; Skehel, J.J.; Wiley, D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387(6631), 426-430.
21. Cavrois, M.; De Noronha, C.; Greene, W.C. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat. Biotechnol. 2002, 20(11), 1151-1154.
22. Kiser, R.; Makovsky, S.; Terpening, S.J.; Laing, N.; Clanton, D.J. Assessment of a cytoprotection assay for the discovery and evaluation of anti-human immunodeficiency virus compounds utilizing a genetically-impaired virus. J. Virol. Methods 1996, 58(1-2), 99-109.
23. Hahnefeld, C.; Drewianka, S.; Herberg, F.W. Determination of kinetic data using surface plasmon resonance biosensors. Methods Mol. Med. 2004, 94, 299-320.
24. Jonsson, U.; Fagerstam, L.; Ivarsson, B.; Johnsson, B.; Karlsson, R.; Lundh, K.; Lofas, S.; Persson, B.; Roos, H.; Ronnberg, I.; et al. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. Biotechniques 1991, 11(5), 620-627.
25. Jonsson, U.; Fagerstam, L.; Lofas, S.; Stenberg, E.; Karlsson, R.; Frostell, A.; Markey, F.; Schindler, F. Introducing a biosensor based technology for real-time biospecific interaction analysis. Ann. Biol. Clin. (Paris) 1993, 51(1), 19-26.
26. Malmqvist, M. Biospecific interaction analysis using biosensor technology. Nature 1993, 361(6408), 186-187.
27. Andersen, J.L.; DeHart, J.L.; Zimmerman, E.S.; Ardon, O.; Kim, B.; Jacquot, G.; Benichou, S.; Planelles, V. HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog. 2006, 2(12), e127.
28. Aiken, C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 1997, 71(8), 5871-5877.
29. Schlegel, R.; Dickson, R.B.; Willingham, M.C.; Pastan, I.H. Amantadine and dansylcadaverine inhibit vesicular stomatitis virus uptake and receptor-mediated endocytosis of alpha 2-macroglobulin. Proc. Natl. Acad. Sci. USA 1982, 79(7), 2291-2295.
30. Superti, F.; Seganti, L.; Ruggeri, F.M.; Tinari, A.; Donelli, G.; Orsi, N. Entry pathway of vesicular stomatitis virus into different host cells. J. Gen. Virol. 1987, 68, 387-399.
31. Beer, C.; Andersen, D.S.; Rojek, A.; Pedersen, L. Caveola-dependent endocytic entry of amphotropic murine leukemia virus. J. Virol. 2005, 79(16), 10776-11787.
32. von Laer, D.; Thomsen, S.; Vogt, B.; Donath, M.; Kruppa, J.; Rein, A.; Ostertag, W.; Stocking, C. Entry of amphotropic and 10A1 pseudotyped murine retroviruses is restricted in hematopoietic stem cell lines. J. Virol. 1998, 72(2), 1424-1430.
33. Este, J.A.; Telenti, A. HIV entry inhibitors. Lancet 2007, 370(9581), 81-88.
34. Akkina, R.K.; Walton, R.M.; Chen, M.L.; Li, Q.X.; Planelles, V.; Chen, I.S. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 1996, 70(4), 2581-2585.
35. Miller, A.D. Human gene therapy comes of age. Nature 1992, 357(6378), 455-460.
36. Parsons, A.B.; Lopez, A.; Givoni, I.E.; Williams, D.E.; Gray, C.A.; Porter, J.; Chua, G.; Sopko, R.; Brost, R.L.; Ho, C.H.; Wang, J.; Ketela, T.; Brenner, C.; Brill, J.A.; Fernandez, G.E.; Lorenz, T.C.; Payne, G.S.; Ishihara, S.; Ohya, Y.; Andrews, B.; Hughes, T.R.; Frey, B.J.; Graham, T.R.; Andersen, R.J.; Boone, C. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 2006, 126(3), 611-625.
37. Callahan, M.K.; Popernack, P.M.; Tsutsui, S.; Truong, L.; Schlegel, R.A.; Henderson, A.J. Phosphatidylserine on HIV envelope is a cofactor for infection of monocytic cells. J. Immunol. 2003, 170(9), 4840-4845.
38. Volpon, L.; Besson, F.; Lancelin, J.M. NMR structure of active and inactive forms of the sterol-dependent antifungal antibiotic bacillomycin L. Eur. J. Biochem. 1999, 264(1), 200-210.
39. Campbell, S.M.; Crowe, S.M.; Mak, J. Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J. Clin. Virol. 2001, 22(3), 217-227.
40. Raulin, J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog. Lipid Res. 2002, 41(1), 27-65.
41. Simons, K.; Ikonen, E. Functional rafts in cell membranes. Nature 1997, 387(6633), 569-572.
42. Maddon, P.J.; Dalgleish, A.G.; McDougal, J.S.; Clapham, P.R.; Weiss, R.A.; Axel, R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47(3), 333-348.
43. Wei, X.; Decker, J.M.; Liu, H.; Zhang, Z.;, Arani, R.B.; Kilby, J.M.; Saag, M.S.; Wu, X.; Shaw, G.M.; Kappes, J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46(6), 1896-1905.
44. Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Wu, X.; O'Brien, W.A.; Ratner, L.; Kappes, J.C.; Shaw, G.M.; Hunter, E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74(18), 8358-8367.
45. Platt, E.J.; Wehrly, K.; Kuhmann, S.E.; Chesebro, B.; Kabat, D., Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72(4), 2855-2864.
46. Nara, P.L.; Fischinger, P.J. Quantitative infectivity assay for HIV-1 and-2. Nature 1988, 332(6163), 469-470.
47. Nara, P.L.; Hatch, W.C.; Dunlop, N.M.; Robey, W.G.; Arthur, L.O.; Gonda, M.A.; Fischinger, P.J. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res. Hum. Retroviruses 1987, 3(3), 283-302.
48. Lyerly, H.K.; Reed, D.L.; Matthews, T.J.; Langlois, A.J.; Ahearne, P.A.; Petteway, S.R., Jr.; Weinhold, K.J. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res. Hum. Retroviruses 1987, 3(4), 409-422.
49. Trkola, A.; Matthews, J.; Gordon, C.; Ketas, T.; Moore, J.P. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J. Virol. 1999, 73(11), 8966-8974.
50. Murakami, T.; Freed, E.O. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc. Natl. Acad. Sci. USA 2000, 97(1), 343-348.
51. Freed, E.O.; Englund, G.; Martin, M.A. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J. Virol. 1995, 69(6), 3949-3954.
52. Han, J.Y.; Zhao, Y.; Anderson, W.F.; Cannon, P.M. Role of variable regions A and B in receptor binding domain of amphotropic murine leukemia virus envelope protein. J. Virol. 1998, 72(11), 9101-9108.
53. Challita-Eid, P.M.; Klimatcheva, E.; Day, B.T.; Evans, T.; Dreyer, K.; Rimel, B.J.; Rosenblatt, J.D.; Planelles, V. Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein. AIDS Res. Hum. Retroviruses 1998, 14(18), 1617-1624.
54. Langlade-Demoyen, P.; Michel, F.; Hoffenbach, A.; Vilmer, E.; Dadaglio, G.; Garicia-Pons, F.; Mayaud, C.; Autran, B.; Wain-Hobson, S.; Plata, F. Immune recognition of AIDS virus antigens by human and murine cytotoxic T lymphocytes. J. Immunol. 1988, 141(6), 1949-1957.
55. Gallo, S.A.; Sackett, K.; Rawat, S.S.; Shai, Y.; Blumenthal, R. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J. Mol. Biol. 2004, 340(1), 9-14.
56. Tobiume, M.; Lineberger, J.E.; Lundquist, C.A.; Miller, M.D.; Aiken, C. Nef does not affect he efficiency of human immunodeficiency virus type 1 fusion with target cells. J. Virol. 2003, 77(19), 10645-10650.
57. Garlickn, R.L.; Kirschner, R.J.; Eckenrode, F.M.; Tarpley, W.G.; Tomich, C.S. Escherichia coli expression, purification, and biological activity of a truncated soluble CD4. AIDS Res. Hum. Retroviruses 1990, 6(4), 465-479.